Neonatal encephalopathy consequent on perinatal hypoxia-ischaemia occurs in 1--3/1000 term births in the developed world and frequently leads to serious and tragic consequences that devastate lives and families, with huge financial burdens for society.[@b1] Although the recent introduction of cooling represents a significant advance, despite treatment around 40% survive with adverse neurodevelopmental function.[@b2] There is an unmet need for novel, safe and effective therapies to optimise brain protection following brain injury around birth. Pre-clinical[@b3] and clinical studies[@b4] have emphasised the importance of sedation to realise the full benefit of therapeutic hypothermia. There is also increasing evidence that infection/inflammation plays a part in the pathogenesis of neonatal encephalopathy in both high- and low-income socioeconomic groups.[@b5] A sedative that enhances macrophage phagocytosis and bacterial clearance, minimising inflammation-induced brain injury would be particularly useful in these patients.

Dexmedetomidine is a highly selective α~2~-adrenoreceptor agonist that confers sedative, anti-inflammatory, analgesic, sympatholytic and organ-protective properties.[@b6] Many of these properties, including sedation, are transduced via α~2~-adrenoreceptor signalling,[@b7] although imidazoline receptor signalling may also contribute to the cardiovascular and organ-protective properties.[@b8] Dexmedetomidine has extensive experimental support for its neuroprotective effects via both α~2~- and non-α~2~-adrenoceptor-mediated mechanisms of action[@b9]--[@b12] and has shown neuroprotection in neonatal models of hypoxic-ischemic brain injury[@b13] and anaesthetic brain injury in rodents.[@b14]--[@b16] Dexmedetomidine has superior anti-inflammatory effects compared with other sedative drugs and may protect against sepsis-induced brain and other organ injury.[@b17],[@b18]

During therapeutic hypothermia (core body cooling to 33.5°C for 72 h within 6 h of birth) in ventilated infants with moderate to severe neonatal encephalopathy, the current practice in most neonatal intensive care units includes sedation with a morphine infusion to minimise discomfort.[@b19] In rodent studies, however, opioids have been seen to augment hypoxic-ischaemic neuronal damage[@b20] in contrast to dexmedetomidine, which was neuroprotective.[@b9],[@b13] Dexmedetomidine use has been described in premature neonates[@b21],[@b22] term neonates[@b23],[@b24] and infants.[@b24],[@b25] Dexmedetomidine may be associated with dose-dependent cardiovascular effects in children; such effects may be opposing and depend on central or peripheral actions.[@b25]--[@b27] Specifically, bradycardia, hypotension and hypertension may occur to varying degrees depending on the plasma concentration.[@b28] Therefore, close monitoring of circulatory dynamics and careful dose titration of dexmedetomidine has been recommended; this is particularly important under hypothermic conditions where there is potential for altered drug pharmacokinetics and pharmacodynamics.[@b29] Specific studies in the newborn are also vital because dexmedetomidine clearance has been reported to be one third that described in adults, rapidly increasing to 85% of the adult value by 1 year of age.[@b23]

Pharmacokinetic (PK) studies are therefore needed prior to pre-clinical neonatal studies of dexmedetomidine neuroprotection with hypothermia. The aim of this study was to investigate the influence of hypothermia and hypoxia-ischaemia on dexmedetomidine pharmacokinetics in a piglet perinatal asphyxia model.

Methods
=======

Anaesthesia and surgical preparation
------------------------------------

All animal experiments were performed under UK Home Office Guidelines \[Animals (Scientific procedures) Act, 1986\]. Ten male piglets aged less than 24 h, with a weight range of 1.6--2.0 kg were anaesthetised and surgically prepared as described previously.[@b30] Briefly, piglets were sedated with intramuscular midazolam (0.2 mg/kg), and arterial oxygen saturation (SpO~2~) was monitored (Nonin Medical, Plymouth, MN, USA). Isoflurane anaesthesia (4% v/v; Abbott Laboratories, Maidenhead, Berkshire, UK) was initially given through a facemask to facilitate tracheostomy and intubation and was used for maintenance anaesthesia (3% during surgery and 2% otherwise). Piglets were mechanically ventilated; ventilator settings were adjusted to maintain partial pressure of oxygen (PaO~2~) and carbon dioxide (PaCO~2~) at 8--13 kPa and 4.5--6.5 kPa, respectively, allowing for temperature and fraction of inspired oxygen (FiO~2~) correction of the arterial blood sample.

A double-lumen umbilical venous catheter (Vigon, Ecouen, France) was inserted for infusion of maintenance fluids (10% dextrose, 60 ml/kg/day before insult and 40 ml/kg/day after resuscitation), fentanyl (3--6 μg/kg/h; Mercury Farmer, Berlin, Germany), and antibiotics \[benzylpenicillin (Genus Pharmaceutical, Newbury, Berkshire, UK) 50 mg kg, every 12 h and gentamicin (Patheon, Swindon, Wiltshire, UK) 4 mg/kg, once a day\] through one lumen and the other lumen was kept for dexmedetomidine infusion only. An umbilical arterial catheter (Vigon) was inserted for continuous monitoring of heart rate and arterial blood pressure, and intermittent blood sampling was used to measure plasma dexmedetomidine concentrations, PaO~2~, PaCO~2~, pH, electrolytes, glucose and lactate (data not shown, Abbot Laboratories). Bolus infusions of 0.9% saline (Baxter, Thetford, Norfolk, UK; 10 ml/kg), dopamine and dobutamine (5--20 μg/kg/min), adrenaline (0.1--1.5 μg/kg/min) and noradrenaline (0.02--1 μg/kg/min) maintained mean arterial blood pressure above 40 mmHg. All animals received continuous physiological monitoring (SA Instruments Inc, Stony Brook, NY, USA) and intensive life support throughout the study. Arterial lines were maintained by infusing 0.9% saline solution (Baxter; 0.3 ml/h); heparin sodium was added at a concentration of 0.5 IU/ml to prevent line blockage.

Both common carotid arteries were surgically isolated at the level of the fourth cervical vertebra and encircled by remotely controlled vascular occluders (OC2A, In Vivo Metric, Healdsburg, CA, USA). After surgery, piglets were positioned prone in a plastic pod, and the head was immobilised securely below the magnetic resonance spectroscopy (MRS) surface coil on each side.

Cerebral hypoxia-ischaemia
--------------------------

In the MRS system, transient hypoxia-ischaemia was induced by remote occlusion of both common carotid arteries, using inflatable vascular occluders and also reducing FiO~2~ to 0.09. During transient hypoxia-ischaemia, cerebral energetic changes were monitored every 2 min by phosphorus-31 (^31^P) MRS and the β-nucleotide triphosphate (NTP; mainly ATP) peak height was automatically quantified. Once the β-NTP peak height had fallen to 40% of baseline, titration began by adjusting FiO~2~ to maintain the β-NTP peak height at 35% (30--40%) of baseline value for 12.5 min. At the end of this 12.5-min period, the animal was resuscitated by deflating the occluders and increasing FiO~2~ to 0.21. ^31^P magnetic resonance spectra were acquired for a further 1 h to follow recovery after resuscitation. Acute energy depletion (AED) was calculated by the time integral of the change in β-NTP peak area relative to the exchangeable phosphate pool \[EPP; EPP = inorganic phosphate (Pi) + phosphocreatine (PCr) + (2γ + β) − nucleotide triphosphate (NTP)\] during hypoxia-ischaemia and the first 60 min after resuscitation as described previously.[@b30]

Experimental groups
-------------------

Before transient hypoxia-ischaemia, baseline data were acquired after stabilisation of the animal in the MRS system. After resuscitation, piglets were administered dexmedetomidine in combination with hypothermia. Fentanyl infusion was stopped following dexmedetomidine bolus and was substituted by dexmedetomidine infusion. Whole body cooling was achieved in less than 90 min using a water mattress and maintained for a total of 18--24 h at target rectal temperature of 33.5°C. Dexmedetomidine was administered with a loading dose of 1 μg/kg over 20 min and then infused for 46--48 h at the following doses: i) 10 μg/kg/h started at 4 h after hypoxic ischemic insult (HI), *n* = 1; ii) 2--10 μg/kg/h variable dose started with 2 μg/kg/h at 4 h with increments of 2 μg/kg/h 4 hourly, *n* = 1; iii) 1.5 μg/kg/h started at 4 h after hypoxia-ichaemia, *n* = 1; iv) 1.5 μg/kg/h started at 30 min post hypoxia-ischaemia, *n* = 3; v) 0.8 μg/kg/h started at 30 min post hypoxia-ischaemia, *n* = 1; vi) 0.6 μg/kg/h started at 30 min post hypoxia-ischaemia, *n* = 2; vii) 1.5 μg/kg/h as control with no hypoxia-ischaemia, *n* = 1. Piglets were cooled: group i, ii and iii had cooling from 2--26 h post HI while group iv, v and vi had cooling from 4--22 h post hypoxia-ischaemia (Table [1](#tbl1){ref-type="table"}). Group vii was not cooled. A solution of 4 μg/ml dexmedetomidine was made by adding 200 μg (2 ml) dexmedetomidine to 48 ml 10% glucose and used for infusion.

###### 

Summary of the dexmedetomidine maintenance dose, start time and cooling periods in relation to the hypoxic-ischaemic insult

  Dexmedetomidine maintenance dose (μg/kg/h)   Start time of dexmedetomidine dose   Cooling period   Number (*n*)
  -------------------------------------------- ------------------------------------ ---------------- --------------
  10                                           4                                    2--26            1
  2--10                                        4                                    2--26            1
  1.5                                          4                                    2--26            1
  1.5                                          0.5                                  4--22            3
  0.8                                          0.5                                  4--22            1
  0.6                                          0.5                                  4--22            2
  1.5                                          --                                   No cooling       1

At the end of hypothermic treatment, piglets were re-warmed at rate of 0.5°C/h to normothermia (38.5°C for a piglet). Blood for dexmedetomidine PK assay was sampled at baseline (pre-insult), 0.5, 1, 2, 6, 9, 12, 24 and 48 h post-insult. Blood for chemistry and blood gas analysis was taken at baseline and then every 6 h post hypoxic ischaemic insult (data not shown).

PK analysis
-----------

### Population parameter estimations

A one-compartment linear disposition model was used to fit data to the PK model. Population parameter estimates were obtained using non-linear mixed effects modelling (NONMEM VII, Globomax LLC, Hanover, MD, USA).[@b31] This model accounts for population parameter variability (between subjects) and residual variability (random effects) as well as parameter differences predicted by covariates (fixed effects). The population parameter variability in model parameters was modelled by a proportional variance model. An additive error (ERR~ADD~) and a proportional term error term (ERR~PROP~) were used to characterise the residual unknown variability. The variance of the residual unidentified variability, η~RUV,i~, was estimated.[@b32] The population mean parameters, between subject variance and residual variance were estimated using the first-order conditional interaction estimate method using ADVAN1 TRANS2. Convergence criterion was three significant digits. A Compaq Digital Fortran Version 6.6A compiler with Intel Celeron 333 MHz CPU (Intel Corp., Santa Clara, CA, USA) under MS Windows XP (Microsoft Corp., Seattle, WA, USA) was used to compile NONMEM. The population parameter variability is modelled in terms of random-effect (*η*) variables. Each of these variables is assumed to have mean 0 and a variance denoted by *ω*,[@b2] which is estimated. The covariance between two elements of *η* \[e.g., clearance (CL) and volume of distribution (V)\] is a measure of statistical association between these two variables. Their covariance is related to their correlation (*R*), i.e.,

The covariance of clearance and distribution volume variability was incorporated into the model.

### Covariate analysis

The parameter values were standardised for a body weight of 70 kg using an allometric model[@b33],[@b34]

where P~i~ is the parameter in the *i*th individual, W~i~ is the weight in the *i*th individual and P~std~ is the parameter in a pig with a weight W~std~ of 70 kg. This standardisation allows comparison of piglet parameter estimates with those reported for adults. The *PWR* exponent was 0.75 for clearance, 0.25 for half times and 1 for distribution volumes.[@b34]

Covariate analysis included a model investigating the impact of temperature on clearance:

where *CLstd* is the population estimates for CL, standardised to a 70 kg pig using allometric models, and *Ftemp* is a constant. Piglets also suffered an episode of AED, where they sustained ischemic brain injury similar to perinatal asphyxia. An additional scaling factor \[hypoxia-ischaemia severity or acute energy depletion factor (FAED)\] was applied to clearance at that time

### Quality of fit

The quality of fit of the PK model to the data was sought by NONMEM\'s objective function and by visual examination of plots of observed vs. predicted concentrations. Models were nested and an improvement in the objective function was referred to the chi-square distribution to assess significance, e.g., an objective function change (ΔOBJ) of 3.84 is significant at α = 0.05.

Bootstrap methods, incorporated within the Wings for NONMEM program, provided a means to evaluate parameter uncertainty.[@b35] A total of 1000 replications were used to estimate parameter confidence intervals. A visual predictive check (VPC),[@b36] a modelling tool that estimates the concentration prediction intervals and graphically superimposes these intervals on observed concentrations after a standardised dose, was used to evaluate how well the model predicted the distribution of observed dexmedetomidine concentrations. Simulation was performed using 1000 subjects with characteristics taken from 10 studied piglets; these simulations were generated by randomly using values from the estimated parameters and their variability. This is an advanced internal method of evaluation[@b37],[@b38] and is considered better than the commonly used plots of observed vs. predicted values.[@b39] For data such as these where covariates such as dose, weight and height are different for each piglet, we used a prediction corrected VPC (PC-VPC).[@b40] Observations and simulations are multiplied by the population baseline value divided by the individual-estimated baseline.

Results
=======

Piglets had a mean age of 22.9 h \[standard deviation (SD) 1.2 h\] and weight 1.76 kg (SD 0.23 kg). The PK analysis included data from 10 piglets that showed substantial variation in plasma concentrations over the 48 h study period (Fig. [1](#fig01){ref-type="fig"}). Plasma dexmedetomidine concentrations were above the safe sedative level in human neonates (0.4--0.8 1 μg/ml) in all but one piglet. Analysis suggested that a two-compartment model was not superior to a one-compartment model (ΔOBJ 5.560 despite two additional parameters required for the two-compartment model). Population parameter estimates (between-subject variability) were CL 3.52 l/h 70 kg \[coefficient of variation (CV) 46.6%\] and V 235 l 70/kg (109.1%). The correlation of between-subject variability for CL and V was −0.756. Temperature reduced clearance (ΔOBJ 3.86); CL was reduced 32.7% at a temperature of 33.5°C. The hypoxic-ischaemic insult had further impact (ΔOBJ 11.15), reducing CL by 55.8%. These parameter estimates are shown in Table [2](#tbl2){ref-type="table"}. The satisfactory PC-VPC plot for these PK data is shown in Fig. [2](#fig02){ref-type="fig"}. From these analyses, we propose that dexmedetomidine 2 μg/kg followed by an infusion of 0.028 μg/kg/h when combined with hypothermia following hypoxic-ischaemic brain injury will provide a dexmedetomidine concentration of 0.5--0.6 μg/l.

![Dexmedetomidine plasma concentrations from nine piglets at varying infusion rates following hypoxic-ischaemic brain injury and co-administration with hypothermia. One additional piglet did not incur brain injury and did not undergo hypothermia. The safe sedative concentration in human neonates is 0.4--0.8 μg/ml; the dotted line is at 1 μg/ml. All piglets achieved dexmedetomidine concentrations above 1 μg/ml.](aas0058-0733-f1){#fig01}
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Standardised population pharmacokinetic parameter estimates

  Parameter           Estimate   %BSV           95%CI
  ------------------- ---------- -------------- ---------------
  CLstd (l/h/70 kg)   3.52       46.6           1.35, 9.01
  Vstd (l/70 kg)      236        191            85.8, 497
  Ftemp               0.0934     --             0.0127, 0.244
  FEAD                0.558      2.6            0.329, 1.21
  Err~ADD~ (mcg/l)    0.171      η~RUV~ 0.643   0.0356, 0.657
  Err~PROP~ (%)       26         4.5, 48.9      

BSV is the between-subject variability, CI is the confidence interval of the structural estimate; CLstd is the standardised clearance; Vstd is the standardised volume; additive and proportional error term respectively are Err~ADD~ and Err~PROP~.

FAED - acute energy depletion factor.

![Visual predictive check for the dexmedetomidine pharmacokinetic (PK) model. All plots show median and 90% intervals (solid and dashed lines). Left hand plot shows all prediction corrected observed concentrations. Right hand plot shows prediction corrected percentiles (10%, 50%, 90%) for observations (lines with symbols) and predictions (lines) with 95% confidence intervals for prediction percentiles (gray shaded areas).](aas0058-0733-f2){#fig02}

Haemodynamic instability was noted in piglets over study period with episodes of bradycardia, hypotension and hypertension (Table [3](#tbl3){ref-type="table"}). Seven out of the nine piglets who received a hypoxic-ischaemic insult experienced cardiac arrest. All haemodynamic adverse events occurred in piglets with plasma concentrations greater than 1 μg/l.

###### 

Dexmedetomidine infusion rates and plasma concentrations for each piglet. The timing of the hypothermia (cooling to 33.5°C; HT), normothermia (NT) and rewarming (RW) phases are shown. The timing of the cardiac arrest and resuscitation are shown for those subjects with these events. The oxygen saturation (O2 sats), heart rate (HR) and mean arterial blood pressure (MABP) for time points corresponding to when dexmedetomidine plasma levels were taken are shown. (BL: baseline)

  Piglet     DEX dose μg/kg/h   Time    DEX plasma level (μg/ml)   Temp   Arrests?              O~2~ Sats %   HR Beat/min   MABP
  ---------- ------------------ ------- -------------------------- ------ --------------------- ------------- ------------- --------
  Study 1                                                                                                                   
  1-1        0                  BL      --                         NT                           98            136           37
  1-2        0                  0.5 h   --                         NT                           98            140           55
  1-3        0                  1 h     --                         NT                           97            147           56
  1-4        1.5                6 h     --                         HT                           98            98            54
  1-5        1.5                9 h     3.412                      HT                           98            90            46
  1-6        1.5                12 h    4.473                      HT                           98            98            47
  1-7        1.5                24 h    6.916                      RW     Fatal arrest          100           94            37
  Study 2                                                                                                                   
  2-1        0                  BL      --                         NT                           98            133           45
  2-2        1.5                0.5 h   1.047                      NT                           98            132           51
  2-3        1.5                1 h     1.226                      NT                           97            136           49
  2-4        1.5                2 h     1.713                      NT                           97            135           46
  2-5        1.5                6 h     3.191                      NT                           95            137           52
  2-6        1.5                9 h     3.855                      NT                           98            145           50
  2-7        1.5                12 h    5.141                      NT                           99            147           51
  2-8        1.5                24 h    8.052                      NT                           98            149           49
  2-9        1.5                48 h    8.115                      NT                           97            135           56
  Study 3                                                                                                                   
  3-1        0                  BL      --                         NT                           99            154           42
  3-2        1.5                0.5 h   --                         NT                           96            166           53
  3-3        1.5                1 h     2.179                      NT                           99            130           46
  3-4        1.5                2 h     2.636                      NT                           99            131           48
  3-5        1.5                6 h     3.809                      HT                           99            95            47
  3-6        1.5                9 h     4.307                      HT                           98            92            41
  3-7        1.5                12 h    6.660                      HT                           99            88            33
  3-8        1.5                24 h    13.511                     RW                           99            164           43
  3-9        1.5                48 h    5.877                      NT                           99            189           44
  Study 4                                                                                                                   
  4-1        0                  BL      --                         NT                           98            154           41
  4-2        1.5                0.5 h   1.869                      NT                           98            141           46
  4-3        1.5                1 h     1.685                      NT                           98            140           45
  4-4        1.5                2 h     3.076                      NT                           98            134           46
  4-5        1.5                6 h     4.563                      HT                           99            93            45
  4-6        1.5                9 h     6.656                      HT                           99            84            46
  4-7        1.5                12 h    7.763                      HT                           100           95            45
  4-8        1.5                24 h    9.067                      RW                           97            131           35
  4-9        1.5                48 h    7.470                      NT                           98            127           49
  Study 5                                                                                                                   
  5-1        0                  BL      --                         NT                           99            175           51
  5-2        1.5                0.5 h   --                         NT                           99            187           50
  5-3        1.5                2 h     --                         NT                           94            169           51
  5-4        1.5                6 h     0.929                      HT                           100           111           48
  5-5        1.5                9 h     2.449                      HT                           100           115           50
  5-6        1.5                12 h    3.579                      HT                           100           153           45
  5-7        1.5                18 h    7.065                      HT                           98            117           48
  5-8        1.5                24 h    8.954                      RW                           98            105           33
  5-9        1.5                30 h    --                         NT                           99            143           48
  5-10       1.5                40 h    11.886                     NT                           80            146           34
  5-11       1.5                48 h    6.506                      NT     Fatal arrest          80            146           34
  Study 6                                                                                                                   
  6-1        0                  BL      --                         NT                           **94**        **125**       **44**
  6-2        0                  0.5 h   --                         NT                           91            111           37
  6-3        0.8                1 h     0.930                      NT                           94            100           58
  6-4        0.8                6 h     1.400                      HT                           97            135           60
  6-5        0.8                12 h    2.201                      HT                           96            103           50
  6-6        0.8                16 h    5.767                      HT                           98            173           28
  6-7        0.8                24 h    27.519                     RW     Arrest-resuscitated   98            181           34
  6-8        0.8                30 h    1.620                      NT                           96            178           55
  6-9        0.8                36 h    2.131                      NT                           97            160           78
  6-10       0.8                48 h    1.772                      NT                           97            107           54
  Study 7                                                                                                                   
  7-1        0                  BL      --                         NT                           94            155           35
  7-2        0.6                0.5 h   --                         NT                           93            231           54
  7-3        0.6                1 h     --                         NT                           93            220           43
  7-4        0.6                2 h     0.622                      NT                           95            190           44
  7-5        0.6                6 h     0.082                      HT                           98            154           53
  7-6        0.6                9 h     0.096                      HT                           99            145           72
  7-7        0.6                12 h    0.221                      HT                           98            161           64
  7-8        0.6                18 h    0.353                      HT                           98            125           59
  7-9        0.6                24 h    1.041                      RW     Fatal arrest          99            169           65
  Study 8                                                                                                                   
  8-1        0                  BL      --                         NT                           88            235           45
  8-2        0.6                0.5 h   --                         NT                           90            202           43
  8-3        0.6                1 h     --                         NT                           94            189           35
  8-4        0.6                2 h     --                         NT                           95            185           36
  8-5        0.6                6 h     --                         HT                           97            178           51
  8-6        0.6                9 h     0.276                      HT                           98            158           43
  8-7        0.6                12 h    1.301                      HT                           98            151           44
  8-8        0.6                24 h    3.190                      RW     Fatal arrest                        50            15
  Study 9                                                                                                                   
  9-1        0                  BL      --                         NT                           100           160           58
  9-2        0                  0.5 h   --                         NT                           99            144           61
  9-3        10                 6 h     8.736                      HT                           98            181           49
  9-4        10                 12 h    32.551                     HT                           99            141           41
  9-5        10                 26 h    27.614                     RW                                         175           33
  9-6        10                 30 h    23.353                     NT                           95            173           35
  9-7        10                 36 h    29.608                     NT     Fatal arrest          98            170           35
  Study 10                                                                                                                  
  10-1       0                  BL      --                         NT                           92            160           61
  10-2       0                  0.5 h   --                         NT                           98            167           51
  10-3       0                  2 h     --                         NT                           100           158           46
  10-4       2                  6 h     0.614                      HT                           99            92            38
  10-5       6                  12 h    2.489                      HT                           100           104           54
  10-6       8                  18 h    9.649                      HT                           99            124           40
  10-7       10                 24 h    18.369                     HT     Arrest-resuscitated   99            126           58
  10-8       10                 36 h    39.020                     NT                           95            185           42
  10-9       10                 48 h    44.115                     NT                           96            93            56

Discussion
==========

PK modelling in this piglet perinatal asphyxia model demonstrated that dexmedetomidine plasma concentrations are influenced by both hypothermia and a preceding hypoxic-ischaemic insult. All dexmedetomidine infusion regimens led to plasma concentrations above those associated with sedation in neonates and children (0.4--0.8 μg/l). Adverse cardiovascular events occurred in seven out of nine piglets receiving a dexmedetomidine infusion following hypoxia-ischaemia and therapeutic hypothermia. All haemodynamic adverse events occurred in piglets with plasma concentrations greater than 1 μg/l. These adverse cardiovascular events consisted of episodes of hypotension, bradycardia, hypertension and cardiac arrest; the events occurred at high drug concentrations due to much lower dexmedetomidine clearance than initially hypothesised. Further studies are needed in neonatal animal models to provide information on the safe dexmedetomidine dose for future neuroprotection studies.

Our initial dose was based on a previous study of adult pigs in which an infusion of 20 mcg/kg/h was administered with no adverse haemodynamic effects.[@b41] As we knew that the clearance estimates of dexmedetomidine in neonates are 50% lower than adult values,[@b24] we started with a dexmedetomidine infusion rate that was 50% lower. However, our data suggest that clearance estimates in neonatal piglets following hypoxia-ischaemia and during therapeutic hypothermia are approximately 10% those reported for clearance in adult humans (CL) 42.1 l/h 70/kg (CV 30.9%).[@b24]

In children in intensive care, a plasma concentration of 0.4--0.8 μg/l was associated with safe sedation (using simulation of published infusion rates).[@b24] This is similar to the suggested effective sedative adult plasma concentration range of dexmedetomidine of 0.6--1.25 μg/l. All piglet dexmedetomidine concentrations were higher than 1.0 μg/l. Drug accumulation, attributable to both a poor initial clearance estimate in piglets, and further reduction due to the effects of cooling and preceding hypoxia-ischaemia over the 48 h study period, was associated with cardiovascular problems including bradycardia, hypotension and hypertension, culminating in cardiac arrest in seven piglets (Table [3](#tbl3){ref-type="table"}). Bradycardia and hypotension are likely to have resulted from central α~2A~-adrenergic receptors causing sympatholysis.[@b6] Bradycardia may be a particular problem in the neonate due to the heart\'s relatively fixed stroke volume. In contrast, stimulation of peripheral post-synaptic α~2B~-adrenergic receptors, and α~1~-adrenergic receptors, may be responsible for the pressor effect and hypertension.[@b6] While dexmedetomidine shows 1200-fold selectivity for α~2~- over α~1~-adrenergic receptors, the high concentrations of dexmedetomidine achieved in our study suggest that α~1~- or α~2B~-adrenergic receptors may have contributed to the cardiovascular changes observed.

The findings that both hypoxia and hypothermia reduce dexmedetomidine clearance have important implications to the use of dexmedetomidine in babies with neonatal encephalopathy undergoing cooling. In two children with traumatic head injury undergoing therapeutic hypothermia, clinically significant bradycardia developed with dexmedetomidine; however, plasma concentrations were not measured.[@b42] In adults, the majority (85%) of dexmedetomidine is metabolised in the liver by direct glucuronidation \[5-diphosphoglucuronosyl transferase (UGT1A4 and UGT2B10)\] and 15% by the cytochrome P450 enzymes (CYP450).[@b28] Following perinatal hypoxia-ischaemia, multi-organ failure occurs in some infants, which may include liver dysfunction and decreased cardiac output;[@b43] both factors can reduce dexmedetomidine clearance. CYP450 enzymes are known to be affected by hypothermia; drugs used in neonatal intensive care such as midazolam, fentanyl, propofol, vecuronium, phenobaribitol and propranolol all have reduced clearance.[@b29],[@b44] Hypothermia is thought to change the binding pocket confirmation of the CYP450, reduce the substrate affinity for the CYP450 binding sites and slow the rate of redox reactions performed by CYP450 enzymes.[@b44] The uridine 5-diphosphoglucuronosyl transferase (UGT) activity has also been seen to be reduced with hypothermia in brain-injured adult patients.[@b45]

There are limitations to this study. Our sample size was limited because of the need to minimise the number of animals used for ethical reasons. The data show large variability of parameter estimates; however, future studies are planned with larger numbers and more intense sampling with and without hypothermia or hypoxia-ischaemia. The hepatic clearance is likely to be even more impaired in severe asphyxia than in our piglet hypoxia-ischaemia model (our model induces systemic hypoxia and localised cerebral ischaemia). Therefore, the hepatic hypoxia experienced in our model may be less compared with infants with severe multi-organ failure associated with neonatal encephalopathy.

Our data highlight the importance of understanding the pharmacokinetics of dexmedetomidine for future pre-clinical neuroprotection trials. Sato et al. saw no augmentation of hypothermic neuroprotection with dexmedetomidine in an adult incomplete cerebral ischaemia rodent model; however, plasma concentrations of dexmedetomidine were not measured.[@b46] A biphasic neuroprotective response to low- and high-dose clonidine (another α~2~-adrenergic receptor agonist) was observed in a pre-term fetal sheep study: low-dose clonidine demonstrated a neuroprotective effect whereas high-dose clonidine was associated with hyperglycaemia, more frequent delayed seizures and loss of neuroprotection.[@b47] It is vital that further studies relate plasma dexmedetomidine levels with brain protection to ascertain whether sedative or sub sedative doses are protective. Our PK analysis in a piglet perinatal asphyxia model with therapeutic hypothermia suggests that dexmedetomidine clearance in the piglet is affected by both temperature and prior hypoxic-ischaemic brain injury. Dexmedetomidine clearance may be reduced almost tenfold in the newborn following hypoxic-ischaemic brain injury with subsequent therapeutic hypothermia. From our one-compartment model, we estimate that a bolus of 2 μg/kg dexmedetomidine over 20 min followed by an infusion of 0.028 μg/kg/h dexmedetomidine during therapeutic hypothermia will achieve a plasma concentration of 0.5--0.6 μg/l (concentration associated with sedation in human newborns); this may be a suitable dose to use in pre-clinical studies assessing possible neuroprotective effects of dexmedetomidine following hypoxia-ischaemia. Further PK studies are vital in pre-clinical and clinical neuroprotection studies of dexmedetomidine.

In summary, this PK study in a piglet perinatal asphyxia model demonstrated adverse cardiovascular effects of dexmedetomidine; these cardiovascular events were associated with unexpectedly high dexmedetomiidne plasma levels secondary to reduced clearance due to cumulative effects of both hypothermia and exposure to hypoxia. Dexmedetomidine clearance may be further reduced in severe asphyxia with multi-organ failure. Dexmedetomidine clearance was reduced almost ten-fold in this neonatal asphyxia model compared with adult values, emphasising the critical importance of careful PK studies in the newborn.
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